Waters (WAT) Q1 2025: Instrument Sales Up 11% as Replacement Cycle Drives Momentum
Waters delivered a high-velocity start to 2025, with instrument sales up 11% and recurring revenue growth tracking expectations, driven by a surging replacement cycle and strong pricing power in pharma and industrial markets. Management raised full-year guidance despite tariff headwinds, as operational agility and differentiated innovation offset external volatility. With robust order growth outpacing sales and downstream exposure insulating results, Waters is positioned to leverage secular testing trends and forthcoming reshoring investments.
Summary
- Instrument Replacement Cycle Accelerates: Large pharma, generics, and contract manufacturers drove double-digit instrument demand, fueling outperformance.
- Tariff Mitigation and Pricing Power: Swift supply chain actions and selective surcharges neutralized tariff impact, while premium product innovation sustained price realization.
- Secular Tailwinds in Testing Markets: PFAS and GLP-1 testing, plus India generics growth, underpin a resilient near-term growth outlook.
Performance Analysis
Waters’ Q1 2025 results reinforced its strategic focus on high-volume, regulated applications, with reported sales rising 4% and constant currency sales up 7%, landing at the high end of guidance. Instrument sales led the quarter with 11% growth, fueled by mid-teens expansion in both liquid chromatography (LC, separation science for molecule analysis) and mass spectrometry (MS, molecular identification and quantification), primarily to pharma and industrial customers. Recurring revenue, which includes consumables and services, grew mid-single digits, reflecting a solid installed base and two fewer selling days.
Pharma end-market sales rose 8%, driven by robust replacement activity among large pharma, generics, and contract development and manufacturing organizations (CDMOs, third-party pharma service providers). Industrial markets maintained 6% growth, propelled by PFAS (per- and polyfluoroalkyl substances, environmental contaminants) testing demand, while academic and government posted 3% growth, led by China’s double-digit performance. Order growth outpaced sales, signaling sustained momentum into the next quarters.
- Instrument Growth Outpaces Recurring Revenue: Double-digit instrument expansion reflects early-stage replacement cycle and strong funnel across pharma and industrials.
- Regional Divergence Evident: Asia (notably India and China) outperformed with 13% growth, while Americas and Europe delivered steady, lower-single-digit expansion.
- PFAS and GLP-1 Testing as Growth Catalysts: PFAS-related sales jumped over 90%, and GLP-1 (glucagon-like peptide-1, diabetes/obesity drugs) testing continued to build, both contributing to Waters’ differentiated growth profile.
Gross margin held at 58.2% and adjusted operating margin at 25.5%, consistent with expectations, as tariff mitigation and pricing actions offset cost headwinds. Free cash flow conversion remained robust, supporting debt reduction and future capital deployment flexibility.
Executive Commentary
"Double digit instrument growth drove our performance as customer spending, especially in pharma, exceeded expectations. Demand remained solid across all our end markets and geographies. These results are driven by our strong commercial execution and our steadfast commitment to operational excellence."
Dr. Udit Batra, President & Chief Executive Officer
"Orders growth exceeded sales growth, underscoring our strong momentum. By end market, pharma grew 8%, industrial grew 6%, and academic and government grew 3%. Customer activity remains strong and install-based utilization remains high, with our consistent results supported by our commercial initiatives in service plan attachment, e-commerce adoption, and the launch of new bio-separations columns."
Amol Chawal, Senior Vice President & Chief Financial Officer
Strategic Positioning
1. Downstream Focus and Replacement Cycle Strength
Waters’ business model is anchored in downstream, high-volume, regulated testing applications—primarily pharma QA/QC (quality assurance/quality control) and industrial compliance—which insulates results from macro volatility and research funding cycles. The replacement cycle for LC and MS instruments is well underway, particularly among large pharma, generics, and CDMOs, which together comprise 75% of pharma segment revenue. This focus enables Waters to capture secular growth as customers upgrade to new platforms like Alliance IS HPLC (high-performance liquid chromatography, advanced molecule separation) and Zivo TQ Absolute MS (high-sensitivity mass spectrometry).
2. Innovation and Premium Pricing
Waters’ revitalized portfolio, highlighted by the Alliance IS HPLC and Zivo TQ Absolute, commands premium pricing due to differentiated features and productivity gains. Management reported 200 basis points of like-for-like pricing gains, with selective surcharges for tariffs adding a further 50 basis points. New product launches in both core and adjacent segments (e.g., Empower for multi-angle light scattering, TA division’s polymer and battery testing tools) extend Waters’ reach and reinforce its pricing power.
3. Tariff Response and Supply Chain Agility
Waters rapidly mobilized a cross-functional task force to mitigate a $45 million gross tariff impact, offsetting $35 million through supply chain adjustments, surcharges, and discretionary spend controls. The remaining $10 million net impact is fully absorbed in current margin guidance, with FX tailwinds offsetting any EPS drag. This operational agility demonstrates Waters’ ability to respond to policy changes without compromising earnings momentum.
4. Secular and Idiosyncratic Growth Drivers
PFAS and GLP-1 testing, along with India generics demand, are delivering outsized growth and are expected to add 100–130 basis points of annual growth accretion in the coming years. These idiosyncratic drivers differentiate Waters from peers more exposed to cyclical or research-driven segments. Management also highlighted the potential for future upside from U.S. pharma reshoring and capacity expansions, though these are not yet reflected in guidance.
Key Considerations
Waters’ Q1 demonstrates the value of its downstream focus, innovation-driven pricing, and operational discipline, but investors should weigh the durability of these drivers amid evolving external pressures.
Key Considerations:
- Replacement Cycle Supports Near-Term Growth: Double-digit instrument sales and strong funnel signal early-stage replacement, especially in large pharma and generics.
- Tariff and Policy Volatility Managed: Supply chain agility and customer surcharges have neutralized tariff impacts, but future policy shifts could introduce new complexity.
- China and India Remain Growth Engines: China delivered 5% growth (double digits in A&G), while India approached 20% constant currency expansion, but China’s outlook remains prudently set at low single digits for the year.
- Academic and Government End Market De-Risked: U.S. A&G exposure is now just 3% of revenue, with guidance assuming a 20% decline for the remainder of 2025.
- M&A and Capital Deployment Optionality: Debt reduction restores capacity for accretive M&A or share buybacks, with management emphasizing a preference for strategic fit over deal size.
Risks
Waters’ resilience is partly predicated on downstream demand and regulatory-driven testing, but risks include further escalation of trade barriers, slower-than-expected recovery in research and biotech, and potential customer pushback on surcharges or pricing. While management’s proactive de-risking of A&G and tariffs is prudent, a material slowdown in pharma manufacturing or unforeseen policy shifts could pressure growth and margins.
Forward Outlook
For Q2 2025, Waters guided to:
- Constant currency sales growth of 5% to 7%
- Reported sales growth of 4% to 6%
- Non-GAAP EPS of $2.88 to $2.98 (10% to 13% reported growth)
For full-year 2025, management raised guidance:
- Constant currency sales growth of 5% to 7%
- Adjusted EPS of $12.75 to $13.05 (8% to 10% growth)
Management cited ongoing strength in instrument replacement, recurring revenue stability, and continued PFAS/GLP-1/India tailwinds. U.S. A&G headwinds and tariff impacts are fully reflected in guidance, with additional upside possible from reshoring or regulatory-driven demand.
Takeaways
Waters’ Q1 2025 results showcase a business capitalizing on secular testing trends and instrument replacement, while deftly managing external shocks and preserving growth momentum.
- Instrument Outperformance Anchors Growth: Instrument sales outpaced expectations, with replacement cycle momentum and premium product launches driving demand across pharma and industrials.
- Operational Agility Offsets Macro and Policy Risks: Rapid mitigation of tariff and policy headwinds, combined with strong pricing, preserved margin and earnings outlook.
- Secular and Idiosyncratic Drivers Distinguish Waters: PFAS and GLP-1 testing, plus India generics, provide differentiated growth levers not broadly available to peers.
Conclusion
Waters enters the remainder of 2025 with strong commercial momentum, operational discipline, and a portfolio aligned to secular growth vectors in regulated testing. Prudent guidance and proactive risk management position the company to deliver on raised expectations, with upside potential from policy-driven reshoring and continued innovation adoption.
Industry Read-Through
Waters’ results underscore the resilience of regulated, downstream testing markets even as upstream research and biotech remain pressured. Instrument replacement cycles and secular trends in environmental and pharma testing are accelerating, benefiting suppliers with premium, differentiated platforms and strong customer relationships. Tariff mitigation and supply chain agility are now table stakes for global life sciences tools providers, and pricing power is increasingly tied to innovation and application focus. Peers with higher exposure to academic, government, or biotech research face a more challenging backdrop, while those aligned with manufacturing and compliance-driven demand are better insulated in the current environment.